Chakraborty R, Sharma D, Kapoor DU, Dwivedi A, Khabiya R, Sen S. Implications of metabolic dysfunction associated fatty liver disease in COVID-19. World J Clin Cases 2023; 11(6): 1275-1286 [PMID: 36926128 DOI: 10.12998/wjcc.v11.i6.1275]
Corresponding Author of This Article
Saikat Sen, PhD, Professor, Faculty of Pharmaceutical Science, Assam Down Town University, Gandhinagar, Panikhaiti, Guwahati 781026, Assam, India. saikat.pharm@rediffmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 26, 2023; 11(6): 1275-1286 Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1275
Implications of metabolic dysfunction associated fatty liver disease in COVID-19
Raja Chakraborty, Deepak Sharma, Devesh U Kapoor, Akanksha Dwivedi, Rakhi Khabiya, Saikat Sen
Raja Chakraborty, Institute of Pharmacy, Assam Don Bosco University, Guwahati 782402, Assam, India
Deepak Sharma, School of Medical Sciences, Adamas University, Kolkata 700126, West Bengal, India
Devesh U Kapoor, Department of Pharmacy, Dr. Dayaram Patel Pharmacy College, Bardoli 394601, Gujarat, India
Akanksha Dwivedi, Rakhi Khabiya, Department of Pharmacy, Acropolis Institute of Pharmaceutical Education & Research, Indore 453771, Madhya Pradesh, India
Saikat Sen, Faculty of Pharmaceutical Science, Assam down town University, Guwahati 781026, Assam, India
Author contributions: Chakraborty R and Sen S designed the structure of the paper; Sharma D, Kapoor DU, Khabiya R, and Dwivedi A collected the data; all the authors contributed to the writing of the paper; Chakraborty R and Sen S performed compilation and reviewed the paper.
Conflict-of-interest statement: All the author declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Saikat Sen, PhD, Professor, Faculty of Pharmaceutical Science, Assam Down Town University, Gandhinagar, Panikhaiti, Guwahati 781026, Assam, India. saikat.pharm@rediffmail.com
Received: November 2, 2022 Peer-review started: November 2, 2022 First decision: November 24, 2022 Revised: December 20, 2022 Accepted: January 31, 2023 Article in press: January 31, 2023 Published online: February 26, 2023
Core Tip
Core Tip: Metabolic associated fatty liver disorder (MAFLD) is associated with fat accumulation and inflammation in hepatocytes, thus compromising liver function and making people more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, cytokine storm in SARS-CoV-2 infected MAFLD patients is considered severe and requires urgent attention. In addition, direct hepatic injury caused by SARS-CoV-2, enhanced levels of inflammatory cytokines, declined hepatic mitochondrial activity, compromised immunity, and altered expression of host angiotensin-converting enzyme 2 receptor are considered as some underlying mechanisms. Thus, patients with MAFLD require special attention to protect themselves from the SARS-CoV-2 infection or severe illness caused by SARS-CoV-2.
